Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | EBP | Q15125 | 2/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11962148 | 1.00 | SIGMAR1 (0.56) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL12125120 | 1.00 | SIGMAR1 (0.56) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL12125047 | 1.00 | SIGMAR1 (0.56) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL12617065 | 0.85 | EBP (0.44) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL9922437 | 0.79 | SIGMAR1 (0.69) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL22858956 | 0.79 | SIGMAR1 (0.69) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL10129761 | 0.79 | SIGMAR1 (0.69) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL10129057 | 0.79 | SIGMAR1 (0.69) | SIGMAR1EBPPDK1KDM4EHTT | |
| SCHEMBL31495434 | 0.77 | EBP (0.36) | SIGMAR1EBPATM | |
| SCHEMBL17012154 | 0.76 | SIGMAR1 (0.48) | SIGMAR1EBPPDK1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227234-B1 | SILICOALUMINOPHOSPHATE MOLECULAR SIEVES USING AN ORGANO-1-OXA-4-AZONIUMCYCLOHEXANE COMPOUND | UOP LLC (US) | 2021-05-26 | — | — | EP | claimed |
| CN-112794851-A | 3- (pyridine-3-yl) -7-azaindole derivative PI3K delta inhibitor and preparation method and application thereof | 复旦大学 | 2021-05-14 | — | — | CN | claimed |
| US-20180258058-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | UOP LLC (US) | 2018-09-13 | — | — | US | claimed |
| US-9815706-B2 | Zeolites using an organo-1-oxa-4-azoniumcyclohexane compound | UOP LLC (US) | 2017-11-14 | — | — | US | claimed |
| EP-3227266-A2 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | UOP LLC (US) | 2017-10-11 | — | — | EP | claimed |
| US-9751772-B2 | Aluminophosphate molecular sieves using an organo-1-oxa-4-azoniumcyclohexane compound | UOP LLC (US) | 2017-09-05 | — | — | US | claimed |
| US-20170044120-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | UOP LLC (US) | 2017-02-16 | — | — | US | claimed |
| US-9522896-B2 | Organo-1-oxa-4-azonium cyclohexane compounds | UOP LLC (US) | 2016-12-20 | — | — | US | claimed |
| US-20160159656-A1 | ALUMINOPHOSPHATE MOLECULAR SIEVES USING AN ORGANO-1-OXA-4-AZONIUMCYCLOHEXANE COMPOUND | UOP LLC | 2016-06-09 | — | — | US | claimed |
| US-20160159760-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | UOP LLC | 2016-06-09 | — | — | US | claimed |
| US-20160159655-A1 | ZEOLITES USING AN ORGANO-1-OXA-4-AZONIUMCYCLOHEXANE COMPOUND | UOP LLC | 2016-06-09 | — | — | US | claimed |
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2023183520-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | A2A PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023072273-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | 先声再明医药有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-0103277-A1 | Quaternary ammonium salts of benzofuran derivatives and fungicides containing them | BASF Aktiengesellschaft (DE) | 1984-03-21 | — | — | EP | disclosed |
| US-4421914-A | IMMUNE FUNCTION REGULATORS | TEIJIN LIMITED (JP) | 1983-12-20 | — | — | US | disclosed |
| US-4376776-A | Dibenzofuran derivatives and their use for controlling fungi | BASF AKTIENGESELLSCHAFT (DE) | 1983-03-15 | — | — | US | disclosed |
| EP-0057362-A1 | Dibenzofurane derivatives, process for their preparation and their use as fungicides | BASF Aktiengesellschaft (DE) | 1982-08-11 | — | — | EP | disclosed |
| EP-0049902-A2 | Novel thiazolo(3,2-a)pyrimidines, derivatives thereof, processes for production thereof, and pharmaceutical use thereof | TEIJIN LIMITED (JP) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159760-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | OXSR1, OXER1, OCIAD1 | SIGMAR1 238/4885EBP 1172/4885PDK1 1344/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | SIGMAR1 3941/4885EBP 4209/4885PDK1 1366/4885 |
| US-20180258058-A1 | ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS | OXSR1, OXER1, OCIAD1 | SIGMAR1 238/4885EBP 1172/4885PDK1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.